The Anti-gastroesophageal Reflux Effect of Anvitra Gastric Suspension on Outpatients With Gastroesophageal Reflux Disease
The Anti-gastroesophageal Reflux Effect of Anvitra Gastric Suspension on Outpatients With Gastroesophageal Reflux Disease
NCT ID: NCT06889246 Phase: NA Status: COMPLETED Enrollment: 27 Completion: 2024-12-30
Conditions
GERD (Heartburn, Regurgitation, and Dyspepsia) Frequency, GERD (Heartburn, Regurgitation, and Dyspepsia) Severity
Interventions
Anvitra Gastric Suspension
Summary
This is an open-label, single-center clinical trial evaluating the efficacy and safety of Anvitra Gastric Suspension health supplements in adult patients with gastroesophageal reflux. Participants will be given Anvitra for 14 consecutive days and will continue to be monitored for 7 days after the intervention. The study aims to assess improvements in GERD (gastroesophageal reflux disease) symtoms, as well as monitor adverse events associated with the interventions. Data will be collected over a 22-day period, including screening, treatment, and follow-up phases.
Primary Outcome
GERD Condition Improvement Assessment